| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/10/2011 | WO2011016576A1 Alanine derivatives as inhibitors of apoptosis proteins |
| 02/10/2011 | WO2011016562A1 Ophthalmic composition for silicone hydrogel contact lens |
| 02/10/2011 | WO2011016559A1 Heterocyclic compound and use thereof |
| 02/10/2011 | WO2011016558A1 Method for producing glucosylceramide-containing material |
| 02/10/2011 | WO2011016528A1 Aminopyrazole derivative |
| 02/10/2011 | WO2011016504A1 Nitrogenous-ring acylguanidine derivative |
| 02/10/2011 | WO2011016501A1 Prophylactic or therapeutic agent for cancer |
| 02/10/2011 | WO2011016487A1 Indigocarmine preparation |
| 02/10/2011 | WO2011016472A1 Pyridine and pyrimidine derivatives having ttk-inhibiting activity |
| 02/10/2011 | WO2011016470A1 Sulfone derivative |
| 02/10/2011 | WO2011016469A1 Amide derivative |
| 02/10/2011 | WO2011016468A1 Benzyl piperidine compound |
| 02/10/2011 | WO2011016461A1 Tumor angiogenesis inhibitor |
| 02/10/2011 | WO2011016459A1 Thienooxazepine derivative |
| 02/10/2011 | WO2011016366A1 Cholesterol ester transfer protein inhibitor |
| 02/10/2011 | WO2011016351A1 Dna synthase inhibitors |
| 02/10/2011 | WO2011016234A1 Picolinamide derivatives as ttx-s blockers |
| 02/10/2011 | WO2011016033A1 Amino-alcohol analogues and uses thereof |
| 02/10/2011 | WO2011015984A1 Orally administerable pharmaceutical preparation containing insulin |
| 02/10/2011 | WO2011015964A1 Controlled-release granular compositions containing mesalazine and process for the manufacture thereof |
| 02/10/2011 | WO2011015883A1 Dichloromethane solvate of tiotropium bromide and its use |
| 02/10/2011 | WO2011015758A2 Use of isoleucine n-hexadecanoyl as a volumizing and/or plumping agent for human skin |
| 02/10/2011 | WO2011015728A1 Novel dihydroindolone derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 02/10/2011 | WO2011015658A1 Bis-benzimidazole derivatives as hepatitis c virus inhibitors |
| 02/10/2011 | WO2011015657A1 Phenyl ethynyl derivatives as hepatitis c virus inhibitors |
| 02/10/2011 | WO2011015652A1 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators |
| 02/10/2011 | WO2011015651A1 Use of canthaxanthin compounds |
| 02/10/2011 | WO2011015641A1 Novel viral replication inhibitors |
| 02/10/2011 | WO2011015630A1 Composition for the treatment of cystic fibrosis |
| 02/10/2011 | WO2011015629A1 Derivatives of 2h pyridazin- 3 -ones, their preparation and their use as scd-1 inhibitors |
| 02/10/2011 | WO2011015599A1 Prasugrel in non-crystalline form and pharmaceutical composition thereof |
| 02/10/2011 | WO2011015537A1 Co-therapy for the treatment of epilepsy and related disorders |
| 02/10/2011 | WO2011015523A1 Benzyl-substituted tetracyclic heterocyclic compounds |
| 02/10/2011 | WO2011015509A1 Food formulation comprising glycogen |
| 02/10/2011 | WO2011015360A1 Pharmaceutical compounds of o-desmethyl-tramadol and cox-inhibitors |
| 02/10/2011 | WO2011015349A2 Methods for enhancing the cognitive function |
| 02/10/2011 | WO2011015343A1 Metabotropic glutamate receptor modulators |
| 02/10/2011 | WO2011015289A1 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate |
| 02/10/2011 | WO2011015241A1 Conformationally constrained, fully synthetic macrocyclic compounds |
| 02/10/2011 | WO2011015226A1 Process for the preparation of sterile powdered pharmaceutical compounds in the form of micro and nanoparticles |
| 02/10/2011 | WO2011015219A1 Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers |
| 02/10/2011 | WO2011015037A1 Antiviral compounds and methods of making and using there of cross reference to related applications |
| 02/10/2011 | WO2011014973A2 Conformationally constrained, fully synthetic macrocyclic compounds |
| 02/10/2011 | WO2011014960A1 Process for preparation of over-the-counter gelatin or pectin-based drug delivery |
| 02/10/2011 | WO2010148121A3 Benzothiazole derivatives |
| 02/10/2011 | WO2010146604A3 Processes for preparing metformin hydrochloride |
| 02/10/2011 | WO2010068810A3 Certain substituted amides, method of making, and method of use thereof |
| 02/10/2011 | WO2010008776A9 Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
| 02/10/2011 | WO2010003992A8 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| 02/10/2011 | US20110035817 Siva 3, its preparation and use |
| 02/10/2011 | US20110035232 Methods of treating hepatic encephalopathy |
| 02/10/2011 | US20110034854 Pdt assisted vision correction and scar prevention |
| 02/10/2011 | US20110034719 Process for the preparation of (s)- naproxen 4-nitrooxybutyl ester |
| 02/10/2011 | US20110034694 Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| 02/10/2011 | US20110034685 Method for Purification of Lactose |
| 02/10/2011 | US20110034568 Compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| 02/10/2011 | US20110034565 Psycho-pharmaceuticals |
| 02/10/2011 | US20110034564 Soluble complexes of curcumin |
| 02/10/2011 | US20110034563 Compartment-specific plant extract combination of ginkgo biloba extract and ginseng extract having a tandem effect |
| 02/10/2011 | US20110034562 Psycho-pharmaceuticals |
| 02/10/2011 | US20110034560 Liquid formulations of compounds active at sulfonylurea receptors |
| 02/10/2011 | US20110034559 Cell Repair And Regeneration By Suramin And Related Polysulfonated Naphthylureas |
| 02/10/2011 | US20110034558 DP2 Antagonist and Uses Thereof |
| 02/10/2011 | US20110034557 Antimicrobial compositions and uses thereof |
| 02/10/2011 | US20110034555 Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| 02/10/2011 | US20110034554 Compositions and methods for treating macular degeneration |
| 02/10/2011 | US20110034553 Novel conjugates for treating neurodegenerative diseases and disorders |
| 02/10/2011 | US20110034552 Long-chain oxyaminopolyol based gelator and gel |
| 02/10/2011 | US20110034551 Methods of increasing sarcosine levels for treating schizophrenia |
| 02/10/2011 | US20110034550 Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same |
| 02/10/2011 | US20110034549 Antitumoral Compounds |
| 02/10/2011 | US20110034548 Method for Suspending a Flavonoid in a Beverage |
| 02/10/2011 | US20110034547 Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof |
| 02/10/2011 | US20110034546 Methods to produce rod-derived cone viability factor (rdcvf) |
| 02/10/2011 | US20110034545 Double-stranded lipid-modified rna having high rna interference effect |
| 02/10/2011 | US20110034543 DNA Vaccination For Treatment of Multiple Sclerosis and Insulin-Dependent Diabetes Mellitus |
| 02/10/2011 | US20110034542 Novel synthetic analogs of sphingolipids |
| 02/10/2011 | US20110034541 Inhibitors of DNA Immunostimulatory Sequence Activity |
| 02/10/2011 | US20110034540 Use of the CYP46A1 Gene for the Treatment of Alzheimer's Disease |
| 02/10/2011 | US20110034539 Methods for treating blood coagulation disorders |
| 02/10/2011 | US20110034538 MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Gastric Cancer |
| 02/10/2011 | US20110034537 Compositions and methods for inhibiting expression of cd45 gene |
| 02/10/2011 | US20110034536 Controlling the potential of primate neural stem cells by regulating pax6 |
| 02/10/2011 | US20110034535 Positive controls for expression modulating experiments |
| 02/10/2011 | US20110034534 siRNA compounds and methods of use thereof |
| 02/10/2011 | US20110034533 Compositions and methods modulating mg29 for the treatment of diabetes |
| 02/10/2011 | US20110034532 Modulation of T Cell Signaling Threshold and T Cell Sensitivity to Antigens |
| 02/10/2011 | US20110034531 Use of hdac inhibitors for the treatment of melanoma |
| 02/10/2011 | US20110034530 Process for the preparation of fipronil and analogues thereof |
| 02/10/2011 | US20110034529 Benzene, pyridine, and pyridazine derivatives |
| 02/10/2011 | US20110034528 Elansolids, Novel Natural Metabolites of Flexibacter and Antibiotically Active Derivatives Thereof |
| 02/10/2011 | US20110034527 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| 02/10/2011 | US20110034526 Benzimidazole Compounds |
| 02/10/2011 | US20110034525 Nonsedating alpha-2 agonists |
| 02/10/2011 | US20110034524 Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor |
| 02/10/2011 | US20110034523 Crystalline forms of rufinamide |
| 02/10/2011 | US20110034522 Methods for alleviating deleterious effects of 3-deoxyglucosone |
| 02/10/2011 | US20110034521 Compounds and methods for treating zinc matrix metalloprotease dependent diseases |
| 02/10/2011 | US20110034520 Inhibitors of P38 Map Kinase |
| 02/10/2011 | US20110034519 Nutritional supplements |